{"generic":"Hepatitis B Vaccine Recombinant","drugs":["Engerix-B","Engerix-B Pediatric","Hepatitis B Vaccine Recombinant","Recombivax HB","Recombivax HB Pediatric\/Adolescent"],"mono":{"0":{"id":"5xwqs0","title":"Generic Names","mono":"Hepatitis B Vaccine Recombinant"},"1":{"id":"5xwqs1","title":"Dosing and Indications","sub":[{"id":"5xwqs1b4","title":"Adult Dosing","mono":"<ul><li><b>Hepatitis B; Prophylaxis:<\/b> 20 years or older: 1 dose (1 mL) IM administered on a 3-dose schedule at 0, 1, and 6 months (Engerix-B(R) 20 mcg\/mL; Recombivax HB(R) 10 mcg\/mL)<\/li><li><b>Hepatitis B; Prophylaxis:<\/b> 18 to 19 years: 1 dose (0.5 mL) IM administered on a 3-dose schedule at 0, 1, and 6 months (Engerix-B(R) 10 mcg\/0.5 mL; Recombivax HB(R) 5 mcg\/0.5 mL)<\/li><li><b>Hepatitis B; Prophylaxis:<\/b> Hemodialysis or predialysis, Recombivax HB(R) dialysis formulation 40 mcg\/mL: 40 mcg IM administered on a 3-dose schedule at 0, 1, and 6 months; consider booster dose if antibody levels are less than 10 milli-international units\/mL 1 to 2 months after completing vaccination series and annually thereafter when antibody levels are less than 10 milli-international units\/mL<\/li><li><b>Hepatitis B; Prophylaxis:<\/b> Hemodialysis, Engerix-B(R) 20 mcg\/mL: 40 mcg (2 mL) IM administered simultaneously on a 4-dose schedule at 0, 1, 2, and 6 months; a 40 mcg (2mL) booster should be given if antibody levels decline below 10 milli-international units\/mL assessed by annual antibody testing<\/li><li><b>Hepatitis B; Prophylaxis:<\/b> Immunocompromising conditions, Recombivax HB(R) dialysis formulation 40 mcg\/mL: 40 mcg IM administered on a 3-dose schedule at 0, 1, and 6 months (guideline dosing)<\/li><li><b>Hepatitis B; Prophylaxis:<\/b> Immunocompromising conditions, Engerix-B(R) 20 mcg\/mL: 40 mcg (2 mL) IM administered simultaneously on a 4-dose schedule at 0, 1, 2, and 6 months (guideline dosing)<\/li><\/ul>"},{"id":"5xwqs1b5","title":"Pediatric Dosing","mono":"<ul><li><b>Hepatitis B; Prophylaxis:<\/b> Birth to 18 years: 1 dose (0.5 mL) IM administered on a 3-dose schedule at 0, 1, and 6 months (Engerix-B(R) 10 mcg\/0.5 mL; Recombivax HB(R) 5 mcg\/0.5 mL)<\/li><li><b>Hepatitis B; Prophylaxis:<\/b> (Recombivax HB (R)) alternative dosing, 11 through 15 years: 2-dose series 10 mcg (1 mL) IM administered on a 2-dose schedule at 0 and 4 to 6 months<\/li><li><b>Hepatitis B; Prophylaxis:<\/b> Infants born to mothers positive for hepatitis B surface antigen: 1 dose vaccine plus hepatitis immune globulin 0.5 mL within 12 hours of birth; give second dose 1 to 2 months after birth dose; give third dose at least 8 weeks after second dose and at least 16 weeks after the first dose; final (third or fourth) dose should be given no earlier than age 24 weeks.<\/li><li><b>Hepatitis B; Prophylaxis:<\/b> Infants born to mothers with unknown status for hepatitis B surface antigen: 1 dose vaccine within 12 hours of birth regardless of birth weight; in infants weighing less than 2000 g, administer 1 dose of vaccine plus hepatitis immune globulin; give second dose 1 to 2 months after birth dose; give third dose at least 8 weeks after second dose and at least 16 weeks after the first dose; final (third or fourth) dose should be given no earlier than age 24 weeks.<\/li><\/ul>"},{"id":"5xwqs1b6","title":"Dose Adjustments","mono":"<ul><li><b>infant weight less than 2000 g with mother who is hepatitis B surface-antigen negative:<\/b> defer vaccination until chronological age 1 month or at hospital discharge<\/li><li>infant weight less than 2000 g and mother is hepatitis B surface-antigen positive or unknown; administer 1 dose vaccine and 1 dose hepatitis B immune globulin  within 12 hours of birth; do not count birth dose as first dose in the vaccine series; follow with a full 3-dose standard regimen (total of 4 doses)<\/li><li><b>known or suspected exposure to hepatitis B surface antigen:<\/b> administer hepatitis B vaccine and hepatitis B immune globulin IM simultaneously at separate sites as soon as possible postexposure; administer additional vaccine doses to complete the series<\/li><\/ul>"},{"id":"5xwqs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Hepatitis B; Prophylaxis<br\/>"}]},"3":{"id":"5xwqs3","title":"Contraindications\/Warnings","sub":[{"id":"5xwqs3b9","title":"Contraindications","mono":"severe allergic reaction after a previous dose of any hepatitis B-containing vaccine or to any vaccine component, including yeast <br\/>"},{"id":"5xwqs3b10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- syncope may occur, possibly accompanied by transient neurological signs such as visual disturbance, paresthesia, or tonic-clonic limb movements<\/li><li>Immunologic:<\/li><li>-- diminished immune response may occur in immunocompromised patients, including those receiving immunosuppressive drugs<\/li><li>-- may cause reaction in latex-sensitive individuals because rubber plunger and\/or tip cap prefilled syringes may contain natural latex rubber<\/li><li>Respiratory:<\/li><li>-- apnea has been reported in premature infants; consider medical status of infant and risk\/benefit prior to administration<\/li><li>Other:<\/li><li>-- defer vaccination in patients with moderate or severe acute illness with or without fever unless the benefit of protection outweighs the risk of an adverse reaction<\/li><li>-- for infants who weigh less than 2000 g and mother is HbsAg-negative at infant birth, defer vaccination until 1 month of age or at hospital discharge; if mother is HbsAg-positive or HbsAg-status unknown at infant birth, administer vaccine and hepatitis B immune globulin  within 12 hours of birth; complete vaccination with standard 3-dose schedule (4 total doses)<\/li><li>-- vaccination may not prevent infection in all persons or in persons with unrecognized hepatitis B infection at the time of vaccination<\/li><\/ul>"},{"id":"5xwqs3b11","title":"Pregnancy Category","mono":"<ul><li>C (FDA)<\/li><li>B2 (AUS)<\/li><\/ul>"},{"id":"5xwqs3b12","title":"Breast Feeding","mono":"<ul><li>WHO: Compatible with breastfeeding.<\/li><li>Micromedex: Infant risk is minimal.<\/li><\/ul>"}]},"5":{"id":"5xwqs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Injection site reaction<\/li><li><b>Gastrointestinal:<\/b>Diarrhea, Nausea<\/li><li><b>Neurologic:<\/b>Asthenia (greater than 1%), Headache (1% to 10%)<\/li><li><b>Other:<\/b>Fatigue (14%), Fever, Malaise<\/li><\/ul><b>Serious<\/b><ul><li><b>Hematologic:<\/b>Pancytopenia (rare)<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><\/ul>"},"6":{"id":"5xwqs6","title":"Drug Name Info","sub":{"0":{"id":"5xwqs6b17","title":"US Trade Names","mono":"<ul><li>Engerix-B<\/li><li>Engerix-B Pediatric<\/li><li>Recombivax HB<\/li><li>Recombivax HB Pediatric\/Adolescent<\/li><\/ul>"},"2":{"id":"5xwqs6b19","title":"Class","mono":"Vaccine<br\/>"},"3":{"id":"5xwqs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"5xwqs6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"5xwqs7","title":"Mechanism Of Action","mono":"Hepatitis B vaccine (recombinant) is a noninfectious recombinant DNA hepatitis B vaccine which contains purified surface antigen of the hepatitis B virus. This is obtained from the cultured Saccharomyces cerevisiae cells which carry the surface antigen gene of the virus.<br\/>"},"9":{"id":"5xwqs9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>do not administer IV or INTRADERMALLY<\/li><li>IM is preferred; may be administered subQ in patients at high risk for bleeding<\/li><li>Recombivax HB(R) formulations are interchangeable (except dialysis formulation) provided that total IM volume\/dose does not to exceed 1 mL (ie, standard formulations may be used for vaccination of predialysis\/dialysis patients, however, the dialysis formulation should not be used in nondialysis patients)<\/li><\/ul><\/li><li><b>Intramuscular<\/b><br\/><ul><li>shake well before withdrawal and use<\/li><li>do not mix vaccine in the same syringe with other vaccines<\/li><li>administer in the deltoid area in adults and older children, and the anterolateral thigh in infants and young children; do NOT administer in the gluteal region  because of suboptimal response<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/>may be administered subQ in patients at high risk for bleeding; lower antibody response and increase incidence of local reactions have been observed.<br\/><\/li><\/ul>"},"11":{"id":"5xwqs11","title":"How Supplied","mono":"<ul><li><b>Engerix-B<\/b><br\/>Intramuscular Suspension: 20 MCG\/ML, 10 MCG\/0.5 ML<br\/><\/li><li><b>Engerix-B Pediatric<\/b><br\/>Intramuscular Suspension: 10 MCG\/0.5 ML<br\/><\/li><li><b>Recombivax HB<\/b><br\/>Intramuscular Suspension: 10 MCG\/ML, 40 MCG\/ML<br\/><\/li><li><b>Recombivax HB Pediatric-Adolescent<\/b><br\/>Intramuscular Suspension: 5 MCG\/0.5 ML<br\/><\/li><\/ul>"},"13":{"id":"5xwqs13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause diarrhea, nausea, asthenia, headache, fatigue, fever, or malaise.<\/li><li>Review dosing schedule with patient.<\/li><\/ul>"}}}